tirzepatide systematic review Beyond Diabetes and Obesity: and Meta-Analysis of Multisystem Therapeutic Benefits Efficacy and Safety of Tirzepatide

nausea, diarrhea, vomiting)

Raza A, Ashraf F, Zou X, Zhang X, Tosif H

The majority of patients with a MACE-4 event ( n = 109) were participants in the SURPASS-4 trial investigating a study population with a high cardiovascular risk

Otherwise, product seems to be working well

This initiation dose helps the body adjust and is not intended to be the main dose for blood sugar control

Compounded tirzepatide, formulated by 503A or 503B compounding pharmacies, is currently regulated under FDA compounding pathways and may be available when brand-name supply is constrained or when a personalized dose is clinically indicated